Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight
The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and mainly be driven by an increase in approval of a ...
FibroGen (NASDAQ:FGEN) vs. Roche (OTCMKTS:RHHBY) Head to Head Survey
FibroGen (NASDAQ:FGEN – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the ...
Medicare price talks defended by DoJ as Trump pledges to lower drug prices
Responding to a lawsuit by Novartis (NVS), the U.S. Department of Justice has defended Medicare price negotiations, signaling ...
Dealbreaker on MSN19h
AstraZeneca Secures China Rights to Anemia Drug, Buying FibroGen Unit in $160M Deal
By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...